ChIP-Seq (Chromation immunoprecipitation sequencing)

.

Chip-seq sequencing service

 

Chromatin immunoprecipitation (ChIP) is a powerful method for studying interactions between specific proteins and a genomic DNA region. MRDNA routinely performs ChIP-seq and provide cost effective high quality data, global binding site maps for a protein of interest and robust output. Please visit www.mrdnalab.com

 

 

 

 

 

 

 

 

Our services – MR DNA Laboratory

MR DNA

Illumina HiSeq 2500/200, MiSeq – The HiSeq 2500/2000 sequencing systems offer the … Metagenomics and amplicon sequencing; ChIPSeq  …

 

Functional Genomics

MR DNA

MR DNA offers library prep, sequencing, and basic data analysis services for …Simple ChIPSeq … hiSeq2500, …., sequence the samples

 

High-Throughput Sequencing Center

MR DNA

We provide services for high-throughput next-generation sequencing using the … (ChIPSEQ), RNA discovery and Multiplex sequencing … Pricing forHiSeq 2500 sequencing is based on ……..sequencing run,  …

 

MR DNA Research Laboratory Services

Services. Transcriptomics. mRNA-Seq: Stranded and non-stranded, high levels of multiplexing … ChIPSeq. Transcription factor analysis; Histone modifications

Cancer genomics at MR DNA

Cancer is a type of disease in which cells divide abnormally without control and are able to invade other tissues. One person dies from cancer each minute in the United States. As the population ages, this number is expected to increase. Thus, we need to understand cancer to control and ultimately conquer it. There are more than 100 different types of cancer. Cancer is a genetic disease that can be caused by many changes across the genome. Cancer cells can spread to other parts of the body through the blood and lymph system. As cancer progresses, cells accumulate additional somatic mutations and propagate to form new cancer clones. As a result, most advanced cancers are polyclonal. Monitoring transcriptome and epigenome changes in cancer cells can help answer questions about disease classification, prognosis, and progression (Mardis and Wilson, 2009; Boehm and Hahn, 2011) and there are a variety of sequencing approaches that enable researchers to detect these changes. Next generation sequencing (NGS) has been instrumental in advancing scientific fields related to human disease. Advances in NGS technology are enabling the systematic analyses of whole cancer genomes, providing insights into the landscape of somatic mutations and the great genetic heterogeneity that defines the unique signature of an individual tumor (Wong et al., 2011). We use Illumina’s TruSeq Amplicon – Cancer Panel (TSACP) for cancer genomics studies, a highly multiplexed targeted resequencing assay for detecting somatic mutations. TSCAP provides predesigned, optimized oligonucleotide probes for sequencing mutational hotspots in >35 kilobases (kb) of target genomic sequence. Within a highly multiplexed reaction, 48 genes are targeted with 212 amplicons. The assays begin with hybridization of the pre-mixed, optimized oligonucleotide probes upstream and downstream of the regions of interest. Each probe includes a target capture sequence and an adapter sequence used in a subsequent amplification reaction. An extension- ligation reaction extends across the region of interest, followed by ligation to unite the two probes. Extension-ligation templates are PCR amplified and two unique sample-specific indices are incorporated. The final reaction product contains amplicons that are ready for sequencing (figure 1). TSACP enables highly sensitive mutation detection within important cancer-related genes, including BRAFKRAS, and EGFR. Mutations in these genes are linked to many cancers, including melanoma, colorectal, ovarian, and lung cancer. The analysis of next-generation sequencing data from cancer samples can be challenging. MR DNA offers a number of software options and analysis tools to simplify this process. We at MR DNA routinely perform cancer panel targeting resequecning assay for detecting somatic mutations with large volume of samples and provide cost effective high quality data and robust output from only low input DNA.

References:

  1. Wong KM, Hudson TJ, McPherson JD. Unraveling the genetics of cancer: genome sequencing and beyond. Annu Rev Genomics Hum Genet. 2011;12:407-430.
  2. Boehm JS, Hahn WC. Towards systematic functional characaterization of cancer genomnes. Nat Rev Genet. 2011 Jun 17;12(7):487-498.
  3. Mardis ER, Wilson RK. Cancer genome sequencing: a review. Hum Mol Genet. 2009 Oct 15;18(R2):R163-168.

cancer genomics 10252013-1